-
01 Feb 21
-
The revolution in COVID vaccine development
The new COVID-19 vaccine developed by Pfizer/BioNTech was approved by the EMA last December and now Moderna’s is following suit. Both are based on mRNA technology and represent a very different type of vaccine compared to traditional ones. While the general public is just beginning to discover mRNA technology, Dr. Meike Saul is an expert in RNA research and has worked with Prolytic GmbH for many years. She was invited to give us a better insight into the exciting world of RNA.
We at KYMOS and ASPHALION are long-time partners in providing analytical and regulatory services to international pharma and biotech sectors. Our testimony goes beyond the conventional “CRO trading with UK clients” to overcome internalization barriers. Our respective services are part of a complex international supply chain that makes the effects of Brexit more visible and quantifiable. Quality Control (QC) is one of the most interdisciplinary departments at KYMOS with high demand from international clients, particularly for EU Batch Testing and Release for drug products and IMPs.